1. Home
  2. DTF vs DBVT Comparison

DTF vs DBVT Comparison

Compare DTF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DTF
  • DBVT
  • Stock Information
  • Founded
  • DTF 1991
  • DBVT 2002
  • Country
  • DTF United States
  • DBVT France
  • Employees
  • DTF N/A
  • DBVT N/A
  • Industry
  • DTF Investment Managers
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DTF Finance
  • DBVT Health Care
  • Exchange
  • DTF Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • DTF 78.9M
  • DBVT 67.8M
  • IPO Year
  • DTF N/A
  • DBVT N/A
  • Fundamental
  • Price
  • DTF $11.24
  • DBVT $0.48
  • Analyst Decision
  • DTF
  • DBVT Strong Buy
  • Analyst Count
  • DTF 0
  • DBVT 2
  • Target Price
  • DTF N/A
  • DBVT $6.00
  • AVG Volume (30 Days)
  • DTF 21.1K
  • DBVT 187.5K
  • Earning Date
  • DTF 01-01-0001
  • DBVT 11-06-2024
  • Dividend Yield
  • DTF 3.64%
  • DBVT N/A
  • EPS Growth
  • DTF N/A
  • DBVT N/A
  • EPS
  • DTF 0.44
  • DBVT N/A
  • Revenue
  • DTF N/A
  • DBVT $12,515,000.00
  • Revenue This Year
  • DTF N/A
  • DBVT N/A
  • Revenue Next Year
  • DTF N/A
  • DBVT $2,860.00
  • P/E Ratio
  • DTF $24.34
  • DBVT N/A
  • Revenue Growth
  • DTF N/A
  • DBVT 125.54
  • 52 Week Low
  • DTF $10.29
  • DBVT $0.44
  • 52 Week High
  • DTF $11.19
  • DBVT $2.14
  • Technical
  • Relative Strength Index (RSI)
  • DTF 45.87
  • DBVT 28.23
  • Support Level
  • DTF $11.21
  • DBVT $0.44
  • Resistance Level
  • DTF $11.37
  • DBVT $0.81
  • Average True Range (ATR)
  • DTF 0.07
  • DBVT 0.06
  • MACD
  • DTF -0.00
  • DBVT -0.03
  • Stochastic Oscillator
  • DTF 37.97
  • DBVT 10.60

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTFTax-Free Income Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax consistent with preservation of capital. The fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: